Expression of active human factor IX in transfected cells

Area of Science:

• Biotechnology
• Molecular Biology
• Hematology

Background:

• Hemophilia B (Christmas disease) is a genetic bleeding disorder caused by deficiencies in coagulation Factor IX.
• Current treatments involve plasma-derived products with risks of viral contamination (hepatitis, AIDS).
• A need exists for a pure, safe, and effective source of human Factor IX.

Purpose of the Study:

• To develop a recombinant DNA method for producing biologically active human Factor IX.
• To establish stable mammalian cell lines capable of secreting recombinant Factor IX.
• To demonstrate the therapeutic potential of the produced Factor IX in vitro.

Main Methods:

• Utilized recombinant DNA techniques to insert the human Factor IX gene into cultured cells.
• Employed cotransfection of baby hamster kidney (BHK) cells with Factor IX and selectable marker plasmids.
• Generated stable cell lines for continuous production and secretion of the protein.

Main Results:

• Successfully produced biologically active human Factor IX in cultured mammalian cells.
• Secreted protein demonstrated the ability to reduce clotting time in Factor IX-deficient plasma.
• Confirmed the authenticity of the recombinant protein as human Factor IX.

Conclusions:

• Recombinant DNA technology provides a viable method for producing pure, active human Factor IX.
• This approach offers a potentially safer alternative to plasma-derived Factor IX for hemophilia B patients.
• Further development could lead to improved therapies for bleeding disorders.